| Date | Title | Description |
| 07.05.2025 | InflaRx Reports First Quarter 2025 Financial Results and Provides Business Update | Announces successful completion of sub-chronic and chronic toxicology studies for INF904, supporting long-term dosing in future clinical trials Multiple near-term catalysts anticipated with the potential to substantially de-risk the Company... |
| 20.03.2025 | InflaRx Reports Full Year 2024 Results and Highlights Key Achievements and Expected Milestones | Received European Commission approval for GOHIBIC® (vilobelimab) for the treatment of SARS-CoV-2-induced acute respiratory distress syndrome (ARDS)Achieved 30-patient recruitment milestone in Phase 3 vilobelimab trial in pyoderma gangrenosu... |
| 07.03.2025 | InflaRx Showcases Vilobelimab’s Role in Immuno-Dermatology at the 2025 AAD Annual Meeting | JENA, Germany, March 07, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, today announced the presentation of multiple posters descr... |
| 07.03.2025 | InflaRx Showcases Vilobelimab’s Role in Immuno-Dermatology at the 2025 AAD Annual Meeting | JENA, Germany, March 07, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, today announced the presentation of multiple posters descr... |
| 28.02.2025 | InflaRx to Showcase Vilobelimab’s Role in Immuno-Dermatology at the 2025 AAD Annual Meeting | JENA, Germany, Feb. 28, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, today announced acceptance of all submitted abstracts, feat... |
| 15.01.2025 | InflaRx Receives European Commission Approval for GOHIBIC® (vilobelimab) for the Treatment of SARS-CoV-2-Induced Acute Respiratory Distress Syndrome (ARDS) | JENA, Germany, Jan. 15, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, today announced that the European Commission (EC) has grant... |
| 20.12.2024 | InflaRx Announces First Patient Dosed in Phase 2a Study for Oral C5aR Inhibitor INF904 | JENA, Germany, Dec. 20, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, today announced that the first patient has been dosed in it... |
| 15.11.2024 | InflaRx Receives Positive CHMP Opinion for GOHIBIC® (Vilobelimab) for the Treatment of SARS-CoV-2-Induced Acute Respiratory Distress Syndrome | JENA, Germany, Nov. 15, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, today announced that the Committee for Medicinal Products f... |
| 08.11.2024 | InflaRx Reports Third Quarter 2024 Financial Results and Provides Business Update | Achieved 30-patient recruitment milestone in Phase 3 vilobelimab trial in pyoderma gangrenosum (PG) to enable interim analysis, with guidance for trial size adaptation or futility expected by the end of 2Q 2025InflaRx pipeline highlighted a... |
| 31.10.2024 | InflaRx to Report Third Quarter 2024 Financial Results on November 8 and to Participate in Guggenheim Inaugural Healthcare Innovation Conference | JENA, Germany, Oct. 31, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced that the Company will report its third q... |
| 25.09.2024 | InflaRx Presents Post Hoc Analysis of SHINE Trial of Vilobelimab in Hidradenitis Suppurativa at the 2024 European Academy of Dermatology and Venereology Congress | JENA, Germany, Sept. 25, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, today announced the e-poster presentation of a post hoc an... |
| 03.09.2024 | InflaRx Presents New Preclinical Findings for INF904 at the 19th European Meeting on Complement in Human Diseases | JENA, Germany, Sept. 03, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, today announced the presentation of preclinical data for t... |
| 27.08.2024 | InflaRx Announces Participation in September Investor Events | JENA, Germany, Aug. 27, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced that it will participate in two investor... |
| 08.08.2024 | InflaRx Reports Second Quarter 2024 Financial Results and Provides Business Update | Hosted research and development (R&D) event focused on the differentiation of INF904 and its potential in addressing significant unmet needs in inflammation & immunology (I&I)
Initiation of a Phase 2a study with INF904 in chroni... |
| 01.08.2024 | InflaRx to Report Second Quarter 2024 Results on August 8, 2024 | JENA, Germany, Aug. 01, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced that it will report its second quarter 2... |
| 30.07.2024 | InflaRx to Present New Preclinical Data on INF904 at the 19th European Meeting on Complement in Human Diseases | JENA, Germany, July 30, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, today announced it will present preclinical data on the com... |
| 24.06.2024 | InflaRx’s GOHIBIC (Vilobelimab) Selected for First BARDA-Sponsored Clinical Trial to Evaluate Novel Host-Directed Therapeutics for Acute Respiratory Distress Syndrome (ARDS) | JENA, Germany, June 24, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, announced today that GOHIBIC (vilobelimab) has been sele... |
| 09.03.2024 | bm|t Venture Insights 4/19: The Decade Past, The Decade Ahead | THE 2010S DECADE
bm|t and our Investee-Partners, who are the true drivers of our success, progressed significantly over the last ten years. At the turn of the last decade, just after the financial crisis, we had more insolvencies... |
| 09.03.2024 | bm|t Venture Insights 4/18: Momentum and Nonlinearities | In the example mentioned above, the marble that more quickly transformed its potential energy into kinetic energy was able to carry its gained momentum through the flat section and won the race. We quickly drew parallels to the bus... |
| 09.03.2024 | bm|t Venture Insights 1/18: 15 years of bm|t — A brief History | bm|t is celebrating its 15th birthday in 2018 and some predecessor organizations/funds date back over 20 years. This long and consistent presence and the valuable networks that have been established have allowed us to build a s... |
| 01.02.2024 | Thuringia launches another fund with the Thüringer Zukunftsfonds III | Another capital injection for the Thuringian economy: With the €40 million “Thüringer Zukunftsfonds III” (TZF III), the state is now supporting innovative start-ups and medium-sized companies that want to open up new business... |
| 27.10.2023 | 20 years pioneering Thuringia’s financial landscape: Interview with bm|t CEO Kevin Reeder | In recent years, Germany’s venture capital activity has witnessed robust growth, with regions like Thuringia emerging as prominent hubs for investment opportunities. This particular German state reported record investment fi... |
| 16.05.2023 | WuXi Biologics Announces Manufacturing Partnership with InflaRx to Advance Gohibic for the Treatment of Certain Critically Ill COVID-19 patients | WuXi Biologics is the manufacturing partner of InflaRx for Gohibic (vilobelimab), a first-in-class monoclonal anti-C5a antibody.
InflaRx received emergency use authorization (EUA) from the FDA for Gohibic (vilobelimab) for the treatment of ... |
| 12.04.2023 | FDA Authorizes New Antibody Treatment For Severe Covid-19 | Microbiology illustration of prescription drug in the human systemgetty |
| 05.01.2022 | InflaRx N : 01-2022-InflaRx Announces Presentation at J.P. Morgan Healthcare Conference and Other Investor Events | Jena, Germany, January 5, 2022 - InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, today announced its participation at several investor eve... |
| 09.09.2021 | InflaRx N : 09-2021-InflaRx to Present at the H.C. Wainwright 23rd Annual Global Investment Conference | Jena, Germany, September 9, 2021 - InflaRx (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, announces that Prof. Niels C. Riedemann, Chief Executive Off... |
| 08.09.2021 | InflaRx N : 09-2021-InflaRx to Proceed with Pivotal Development for Vilobelimab in Hidradenitis Suppurativa with New Primary Endpoint | InflaRx received feedback from FDA within its Type A meeting which is supportive of a new primary endpoint measuring reductions in all three inflammatory HS lesions - including reductions of draining tunnels (previously referred to as drain... |
| 12.05.2021 | INFLARX N.V.
InflaRx N : 05-2021-InflaRx Reports First Quarter 2021 Financial & Operating Results | Jena, Germany, May 12, 2021 - InflaRx (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, announced today financial results for the three months ended Marc... |
| 11.05.2021 | INFLARX N.V.
InflaRx N : 05-2021-InflaRx Announces Positive Topline Results for Vilobelimab from the U.S. Phase II ANCA-Associated Vasculitis IXPLORE Study | U.S. IXPLORE Phase II trial achieved its objective; vilobelimab was shown to be safe and well tolerated in patients with ANCA-associated vasculitis when added to current standard of care
EU IXCHANGE Phase II trial is fully enrolled with res... |
| 01.04.2020 | Coronavirus Business Tracker: How The Private Sector Is Fighting The Covid-19 Pandemic | Alain Mérieux, founder of BioMérieux.AFP via Getty Images |
| 30.10.2017 | Term Sheet — Monday, October 30 | I SCAM YOUS
Good morning, Term Sheet readers.
Paid Content How can you protect what you can't see? From ExtraHop
“Thanks in part to the endorsements, in just a few weeks Centra’s founders raised over $30 million from investors around the wo... |
| 13.10.2017 | InflaRx Raises $55M Series D from Bain Capital | InflaRx, the biopharmaceutical company developing new therapeutics in the terminal complement space, announced today a $55M Series D financing and investment round. The round was co-led by Bain Capital Life Sciences LP, Cormorant Asset Mana... |
| - | bm|t Investee Partner InflaRx selected for COVID-19 Therapy Offensive of the German Federal Ministry of Education and Research | The German Federal Ministry of Education and Research has announced the first six funded biotech companies in its COVID-19 therapy initiative, which is being funded with up to €300 million. The funding is intended to financiall... |
| - | InflaRx Doses First Patient in Multicenter Randomized Clinical Trial in Severe Progressed COVID-19 Pneumonia in Europe upon Receipt of Initial Positive Human Data with InflaRx’s anti-C5a Technology | InflaRx has dosed the first patient in an adaptive randomized controlled clinical study with IFX‑1 in patients with severe COVID-19 pneumonia in the Netherlands
InflaRx received initial positive human data from its licensee, Bei... |
| - | bm‑t Beteiligungsmanagement Thüringen GmbH brokers investments of over EUR 45 million in Thuringian companies in 2016 | In the 2016 financial year, more than EUR 45 million flowed from the investor network of bm‑t beteiligungsmanagement thüringen gmbh (bm|t) into its innovative Thuringian portfolio companies. At around EUR 43 million, the maj... |
| - | InflaRx publishes successful results of Phase IIa clinical trial | InflaRx, a biotech company based in Jena, Germany, today published positive data from its exploratory Phase IIa clinical trial with IFX‑1. The trial is for the treatment of hidradenitis suppurativa (HS), a painful, chronic and i... |
| - | Over EUR 150 million flowed into Thuringian portfolio companies of bm‑t beteiligungsmanagement thüringen in 2017 | In the 2017 financial year, over EUR 150 million flowed from private domestic and foreign investors from the network of bm‑t beteiligungsmanagement thüringen gmbh (bm|t), into its innovative Thuringian portfolio companies.
T... |
| - | InflaRx raises another $ 63 Mio in primary shares | InflaRx and current shareholders placed $ 117,3 Mio. of shares, with $ 63 Mio. as primary shares with the proceeds going to InflaRx and $ 54 Mio. as secondary shares with the proceeds going to early shareholders, who all remain inv... |
| - | InflaRx Announces Decision to Enter Phase III Development of IFX‑1 in Severe COVID-19 Induced Pneumonia | 50% lower all-cause mortality rate and other efficacy trends were shown with IFX‑1 in initial data from the randomized exploratory Phase II part of the Phase II/III trial
Subject to regulatory approval, a randomized, double-bli... |
| - | InflaRx, a bm|t Investee-Partner, completed a minimum 75 Mio. USD equity raise, greatly enhancing the company’s ability to continue advancing its promising pipeline through multiple significant milest... | InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, announced today that it has completed its underwritten public off... |
| - | bm|t investment inflaRx from Jena goes public on the US stock exchange NASDAQ | Thuringia-based biotech company inflaRx (NASDAQ: IFRX) successfully completed its initial public offering on the US technology exchange Nasdaq yesterday, raising around $100 million.
The company placed 6,667,000 common shares... |
